Amoéba S.A. (EPA:ALMIB)

Market Cap	37.78M -47.0%
Revenue (ttm)	758.45K +11.1%
Net Income	-11.80M
EPS	n/a
Shares Out	129.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,312,691
Open	0.2500
Previous Close	0.2525
Day's Range	0.2500 - 0.2940
52-Week Range	0.2475 - 1.1200
Beta	0.28
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 24, 2026

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France.

• Industry: Agricultural Inputs
• Sector: Materials
• Founded: 2010
• Employees: 23
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALMIB

Financial Performance

In 2025, Amoéba's revenue was 695,449, an increase of 15.60% compared to the previous year's 601,600. Losses were -8.30 million, 26.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error